Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2015-01267 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| CCCWFU 22A15 | Other Identifier | Comprehensive Cancer Center of Wake Forest University | |
| P30CA012197 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
PRIMARY OBJECTIVES:
I. To determine the metabolic adaptations that occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear cells from acute myeloid leukemia (AML) patients.
OUTLINE:
Patients undergo collection of peripheral blood mononuclear cell (PBMC) samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ancillary-Correlative (metabolic changes) | Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cytology Specimen Collection Procedure | Other | Undergo collection of PBMC samples |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycolytic flux rate | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Level of fatty acid synthase by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Number of mononuclear cells per sample determined by cell isolation | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or analysis of variance (ANOVA) procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Oxygen consumption rate | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Number of viable samples | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Level of hexokinase by western blot |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients with Acute Myeloid Leukemia (AML)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Timothy Pardee | Wake Forest University Health Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Comprehensive Cancer Center of Wake Forest University | Winston-Salem | North Carolina | 27157 | United States |
Not provided
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Peripheral Blood Mononuclear Cells
| Laboratory Biomarker Analysis | Other | Undergo metabolic analysis |
|
Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate.
| Up to 72 hours after starting chemotherapy |
| Level of phosphofructokinase-1 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Level of phosphoglycerate mutase by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Total level of pyruvate kinase M2 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Level of pyruvate kinase M2 for phospho-T105 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| Level of phosphofructokinase-2 by western blot | Results will be analyzed using descriptive statistics. Comparison between groups will be done using t-tests or ANOVA procedures. Other inferential statistical analysis will be conducted as appropriate. | Up to 72 hours after starting chemotherapy |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |